Effect of FC-007 on proliferation, apoptosis and invasion of glioblastoma and its molecular mechanism
张金男,陈广永,孙利波,杨福伟
DOI: https://doi.org/10.3760/cma.j.cn421213-20201120-01421
2021-01-01
Abstract:Objective:To explore the effect of a new immunosuppressant FC-007 on the proliferation, apoptosis and invasion of glioblastoma (GBM) and its molecular mechanism.Methods:Glioblastoma cell lines U87MG and U118MG were cultured in vitro, and cell counting kit-8 (CCK-8) assay was used to detect the proliferation activity of glioma cells treated with different concentrations of FC-007 (0, 0.1, 0.5, 1, 5, 10, 50, 100 μmol/L). Flow cytometry (FCM) was used to detect the effects of different concentrations of FC-007 (0, 10, 20 μmol/L) on the cell cycle and apoptosis of U87MG and U118MG cells. Western blotting was used to detect the effects of different concentrations of FC-007 (0, 25, 50, 100 μmol/L) on the expression of matrix metalloproteinase (MMP)-2 and MMP-9 proteins, and real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) was used to detect the effects of different concentrations of FC-007 (0, 5, 10, 20 μmol/L) on Nrf2 and its downstream genes HO-1, NQO-1 expression levels. The groups were compared by F tests. Results:The results of CCK-8 assay showed that the median proliferation inhibitory concentrations (IC 50) of U87MG and U118MG cells after FC-007 treatment for 48 h were 9.77 and 11.10 μmol/L respectively. The FCM results showed that with the increase of FC-007 concentration, the proportion of cells in the G 0/G 1 phase was significantly higher than that in the blank control group, and the proportion of cells in the S phase was significantly lower than that in the blank control group. The changes in the G2/M phase were not obvious, and the differences were all statistical significance ( F=121.962, 125.478, 129.653, 120.516, 129.340, 122.425, P<0.05). After treatment of gloma cells with FC-007 for 24 h, the apoptosis rate under the concentrations of FC-007 (0, 10, 20 μmol/L) in U87MG cells [(6.4±0.3)%, (18.4±1.2)%, (26.1±1.7)%] and U118MG cells [(5.0±0.7)%, (28.4±5.6)%, (33.1±4.1)%] showed statistically significant difference ( F=265.502, 260.378, P<0.05). Western blotting results showed that FC-007 significantly reduced the expression of MMP-2 and MMP-9 proteins, and the difference was statistically significant ( F=178.835, 182.098, 175.229, 186.427, P<0.05). RT-qPCR results showed that FC-007 could inhibit the expression of Nrf2 and its downstream genes HO-1 and NQO-1 in GBM cells, and the differences were statistically significant ( F=185.998, 187.835, 182.642, 188.517, 187.556, 182.475, P<0.05). Conclusion:FC-007 can reduce the protein levels of MMP-2 and MMP-9, and the mRNA expressions of Nrf2, HO-1 and NQO-1, inhibit the proliferation of glioblastoma cells in a dose-time-dependent manner, promote cell apoptosis, and block the cell cycle in G 0/G 1 phase.